Masimo Corporation: FDA filings under this applicant name
FDA lists 114 510(k) clearances under 2 spellings of the applicant name “Masimo Corporation” (first 1997, latest 2026), plus 2 De Novo decisions, across 15 product codes in 5 review panels. Median 510(k) review time under this name: 104 days. Since 2017 the median was 203 days, against 207 days for all cleared 510(k)s in the same product codes. Related companies, subsidiaries and acquired businesses that file under other applicant names are counted on their own pages, not here.
510(k) clearances per year
| Year | Clearances | Median review days |
|---|---|---|
| 2012 | 4 | 74 |
| 2013 | 1 | 389 |
| 2014 | 2 | 121 |
| 2015 | 1 | 255 |
| 2016 | 5 | 228 |
| 2017 | 3 | 238 |
| 2018 | 3 | 250 |
| 2019 | 5 | 184 |
| 2020 | 5 | 94 |
| 2021 | 3 | 221 |
| 2022 | 3 | 130 |
| 2023 | 6 | 280 |
| 2024 | 3 | 192 |
| 2025 | 3 | 164 |
| 2026 | 4 | 192 |
Review time against the same product codes
Since 2017, 510(k)s cleared under the name Masimo Corporation took a median 203 days from FDA receipt to decision. All cleared 510(k)s in the same product codes over the same years took a median 207 days.
Top product codes
| Product code | Device | Submissions | 510(k) clearances |
|---|---|---|---|
| DQA | Oximeter | 77 | 77 |
| MWI | Monitor, Physiological, Patient (Without Arrhythmia Detection Or Alarms) | 13 | 13 |
| MUD | Oximeter, Tissue Saturation | 6 | 6 |
| MHX | Monitor, Physiological, Patient(With Arrhythmia Detection Or Alarms) | 4 | 4 |
| DPS | Electrocardiograph | 3 | 3 |
| OLW | Index-Generating Electroencephalograph Software | 3 | 3 |
| NLF | Oximeter, Reprocessed | 2 | 2 |
| BZQ | Monitor, Breathing Frequency | 1 | 1 |
| CCK | Analyzer, Gas, Carbon-Dioxide, Gaseous-Phase | 1 | 1 |
| FLL | Continuous Measurement Thermometer | 1 | 1 |
Plus 5 more product codes.
Review panels
- Anesthesiology (84)
- Cardiovascular (22)
- General and Plastic Surgery (6)
- Neurology (3)
- General Hospital (1)
Most recent Masimo Corporation 510(k) clearances
| 510(k) | Device | Product code | Decision date | Review days |
|---|---|---|---|---|
| K260676 | Radius VSM and Accessories | MHX | 2026-10-14 | 226 |
| K253417 | Masimo Root Monitoring System | MWI | 2026-08-12 | 315 |
| K260880 | SedLine Sedation Monitor | OLW | 2026-07-10 | 115 |
| K254209 | Radius VSM and Accessories | MHX | 2026-06-04 | 157 |
| K243324 | Masimo O3 Regional Oximeter | MUD | 2025-07-17 | 267 |
| K250757 | Radius VSM and Accessories | MHX | 2025-05-29 | 78 |
| K243305 | Masimo W1 | DPS | 2025-04-03 | 164 |
| K240229 | Masimo W1 | DPS | 2024-08-08 | 192 |
| K234021 | Masimo Stork | QYU | 2024-05-03 | 135 |
| K214115 | MightySat -OTC | OLK | 2024-01-31 | 762 |
104 earlier clearances. See the full list in Caduvo.
PMA and De Novo decisions
| Number | Pathway | Device | Decision date |
|---|---|---|---|
| DEN200076 | De Novo | Hyperoxia Monitoring Device Adjunct To Pulse Oximetry | 2023-10-12 |
| DEN200011 | De Novo | Monitor For Opioid Induced Impairment Of Oxygenation | 2023-03-31 |
Recalls
16 product recalls in 9 recall events; 10 initiated in the last five years. Most recent: 2026-02-20.
4 product recalls in 1 recall event filed under other recalling-firm names cite a 510(k) or PMA held under this applicant name; 0 initiated in the last five years. Most often: Merge Healthcare, Inc. (4).
These recall records list the clearance number, so the device was cleared under this name. The recalling firm may be the same company under another spelling, a company that acquired the product line, a relabeler or a contract manufacturer. They are not added to the count above.
Recalling firms are matched to this applicant name by name only (same normalization), so related entities that recall under another name are not counted. A recall count says nothing about how safe one company's devices are compared with another's.
Device clinical trials
An industry sponsor named Masimo Corporation is the lead sponsor of 106 device studies on ClinicalTrials.gov (1 active or recruiting). Most recent:
- NCT07223177: Philips FAST SpO2 Technology With Masimo Sensors for SpO2 Monitoring in the Neonatal, Infant, and Pediatric Populations (Recruiting, started 2025-12-17)
- NCT07223164: Validation of the Masimo Irregular Heartbeat Detection Algorithm in Participants Without Cardiovascular Disease (Completed, started 2025-10-21)
- NCT06922461: Clinical Performance of Masimo INVSENSOR00048 (DALI0001) (Terminated, started 2025-05-02)
- NCT06334055: Validation Study of Mean Arterial Pressure (MAP) Parameter of Masimo INVSENSOR00073 (Completed, started 2024-03-04)
- NCT06289556: Clinical Performance of Masimo INVSENSOR00048 (Terminated, started 2024-01-23)
FDA spellings included
FDA records this applicant under 2 spellings (case, punctuation and legal-suffix variants of one name); this page adds them up. Filings per spelling:
- Masimo Corporation (88)
- Masimo Corp. (28)
Frequently asked questions
How many FDA 510(k) clearances are listed under Masimo Corporation?
FDA lists 114 510(k) clearances under 2 spellings of the applicant name “Masimo Corporation” (first 1997, latest 2026), plus 2 De Novo decisions, across 15 product codes in 5 review panels. Filings under other applicant names, such as subsidiaries, are not included.
How long has FDA taken to clear 510(k)s filed by Masimo Corporation?
The median time from FDA receipt to decision across 510(k)s cleared under the name Masimo Corporation is 104 days. Since 2017: 203 days, versus 207 days for all cleared 510(k)s in the same product codes.
Which FDA product codes appear under Masimo Corporation?
The most frequent FDA product codes under this applicant name are DQA (Oximeter, 77); MWI (Monitor, Physiological, Patient (Without Arrhythmia Detection Or Alarms), 13); MUD (Oximeter, Tissue Saturation, 6).
Next steps
- See all 114 Masimo Corporation clearances with predicates and recalls
- Run predicate analysis for product code DQA, Masimo Corporation's most frequent
Compiled by Caduvo from public U.S. government records. Counts cover filings under the applicant names shown on this page only. Review days run from FDA receipt to decision. Not reviewed or endorsed by FDA or any other agency, or by the companies named. Not regulatory advice. Report an error in this data. Data and corrections policy.